STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

@article{Dahal2017STINGAR,
  title={STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.},
  author={L. N. Dahal and Lang Dou and K. Hussain and R. Liu and Alexander Earley and K. Cox and Salome Murinello and Ian P Tracy and F. Forconi and A. J. Steele and P. Duriez and D. Gomez-Nicola and J. Teeling and M. Glennie and M. Cragg and S. Beers},
  journal={Cancer research},
  year={2017},
  volume={77 13},
  pages={
          3619-3631
        }
}
  • L. N. Dahal, Lang Dou, +13 authors S. Beers
  • Published 2017
  • Biology, Medicine
  • Cancer research
  • Tumors routinely attract and co-opt macrophages to promote their growth, angiogenesis, and metastasis. Macrophages are also the key effector cell for mAb therapies. Here we report that the tumor microenvironment creates an immunosuppressive signature on tumor-associated macrophages (TAM), which favors expression of inhibitory rather than activating Fcγ receptors (FcγR), thereby limiting the efficacy of mAb immunotherapy. We assessed a panel of TLR and STING agonists (a) for their ability to… CONTINUE READING
    27 Citations
    Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment
    • 22
    Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression
    • 4
    • PDF
    UC‐1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb‐mediated target cell deletion
    • 4
    • PDF
    Boosting therapeutic potency of antibodies by taming Fc domain functions
    • 11
    • PDF
    Targeting tumor-associated macrophages for cancer immunotherapy.

    References

    SHOWING 1-10 OF 52 REFERENCES
    Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.
    • 84
    • PDF
    Using macrophage activation to augment immunotherapy of established tumours
    • 52
    • PDF
    Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
    • 69
    • PDF
    Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
    • 2,629
    Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
    • 43
    • PDF
    Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy1
    • 93
    • PDF
    Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.
    • 153
    • PDF
    In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
    • J. Brody, W. Ai, +10 authors R. Levy
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 373